DAIC
MARCH 13, 2024
CMS has reviewed the CardiAMP Heart Failure II Trial and approved the investigational product, related and routine items and services for purposes of Medicare coverage. The CardiAMP Heart Failure II Trial is FDA approved to enroll up to 250 patients at up to 40 clinical centers. said Peter Altman , PhD.,
Becker's Hospital Review - Cardiology
SEPTEMBER 3, 2024
have the lowest death rate for heart failure patients in the country, according to CMS data. Chicago-based Northwestern Memorial Hospital and VA Boston Healthcare System-Jamaica Plain (Mass.)
Becker's Hospital Review - Cardiology
AUGUST 14, 2024
Luke's Regional Medical Center has the lowest readmission rate for heart failure patients, CMS found. Boise, Idaho-based St.
Journal of Clinical Investigation - Cardiology
FEBRUARY 17, 2025
Heterozygous truncating variants in the sarcomere protein titin (TTN) are the most common genetic cause of heart failure. A 296 bp fragment of this element, denoted E1, was sufficient to drive expression of a reporter gene in hiPSC-CMs.
Becker's Hospital Review - Cardiology
JANUARY 13, 2025
"CMS proposes Medicare and Medicaid coverage for implantable pulmonary artery pressure sensors to manage heart failure. Final decision to be published on Jan.
DAIC
JULY 25, 2024
FDA granted CardiAMP Cell Therapy a Breakthrough Device Designation for the treatment of ischemic heart failure. Leslie Miller, MD , trial investigator at the CHF Heart Function Clinic at BayCare Morton Plant Hospital in Clearwater, Florida and a member of the CardiAMP Heart Failure II Study Executive Steering Committee. “As
DAIC
MARCH 7, 2024
Results showed reductions in heart death equivalents and MACCE, with a magnified reduction among patients with elevated NTproBNP, a common marker of heart distress. These patients saw more than a 17% lower rate of heart death equivalents at up to two years compared to control patients treated with heart failure medication alone (2.9%
Expert insights. Personalized for you.
111 
Let's personalize your content